(firstQuint)Celgosivir as a Treatment Against Dengue.

 Patients with confirmed dengue fever who meet all inclusion and exclusion criteria will be enrolled and admitted to the Investigational Medicine Unit.

 Patients will be randomized 1:1 to celgosivir or placebo.

 Capsules of placebo or celgosivir will be administered for 5 days.

 While in hospital, daily clinical exams will be conducted, and blood samples will be collected for viral load, quantitative NS1, hematology, clinical chemistry, cytokine levels and pharmacokinetics (PK).

 Safety assessments will be conducted.

 At discharge on Study Day 5, patients will be asked to return on Study Days 7, 10, and 15 for blood sampling and safety assessments.

.

 Celgosivir as a Treatment Against Dengue@highlight

This is a Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study to Evaluate the Activity, Pharmacokinetics, Safety and Tolerability of Celgosivir in Adults with Confirmed Dengue Fever.

